Related Experiment Video
Updated: Mar 14, 2026

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
Artificial intelligence in oncology: Current status and possibilities (Review)
Abhavya Roy1, Apurva Bhoyar2, Ashok Ahirwar3
1University College of Medical Sciences, Guru Teg Bahadur Hospital, Delhi 110095, India.
Abstract:
Artificial intelligence (AI) is increasingly reshaping oncology by enhancing diagnostic accuracy, improving prognostication and enabling personalized treatment planning. The present review aimed to critically synthesize the contemporary landscape of AI applications across cancer imaging, digital pathology, clinical outcome prediction, chemotherapy and radiotherapy. Recent advances in machine learning and deep learning, particularly convolutional neural networks and transformer-based architectures, have demonstrated robust performance in lesion detection, tumour grading, survival prediction and treatment optimization, in several instances approaching or exceeding expert-level accuracy. Despite these advances, translation into routine clinical practice remains limited due to dataset bias, limited generalizability, the lack of standardized data protocols, insufficient interpretability and regulatory barriers. Ethical challenges related to fairness, transparency and equitable access are especially relevant in low- and middle-income countries. Emerging frontiers, including multimodal AI, foundation models, federated learning, and explainable AI, provide potential solutions to these challenges. Multidisciplinary collaboration, rigorous prospective validation and robust ethical governance will be essential to realize the full potential of AI in advancing precision oncology and improving global cancer outcomes.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

